Name: Vitiligo: An Autoimmune Condition With Real Treatments, Not a Diet Failing
Creator: Realised
Published: 2026-06-01

Summary

Vitiligo is an autoimmune disease in which the body's own cytotoxic T cells destroy the pigment-making melanocytes, so the white patches are not a fungal infection, a hygiene lapse, or a food you ate, and there are now genuine evidence-based treatments that can repigment skin (topical steroids and calcineurin inhibitors, narrowband UVB phototherapy, and the first FDA-approved repigmentation drug, the JAK-inhibitor cream ruxolitinib) — yet the honest counter is that there is no cure, repigmentation is slow, partial and strongly site-dependent (the face responds, the hands and feet barely do), e

Why Moderate

Moderate Evidence because the entry blends claims of very different strength. The pathophysiology (autoimmune, CD8+/interferon-gamma) and the regulatory facts (ruxolitinib approved 2022, boxed warning, nonsegmental indication) are high-confidence, and the thyroid-comorbidity association is a strong meta-analytic observation — but the claims that make the entry actionable as treatment sit at Moderate: the ruxolitinib effect is real but modest and face-only; the narrowband-UVB-plus-topical benefit is consistent in direction but modest and heterogeneous; and the site-dependence and "no cure" caveats bound all of it. The entry inherits the confidence of its load-bearing therapeutic claims, which is Moderate.

NOT Foundational because there is no single undisputed axiom to state — the entry carries clinical judgement, a live both-ways tension (real treatments versus partial results and a false-cure market), and commercial-bias weighting.

NOT Strong because the treatment anchors are not gold-standard for the claim that matters to patients: the best drug's evidence is a manufacturer-sponsored pair of trials on a facial endpoint most patients do not reach, and the combination-therapy data are modest and heterogeneous. Only the mechanism, the regulatory facts, and the thyroid association reach high confidence, and the entry marks those explicitly rather than letting them lift the whole verdict.

The per-claim split (read this, not just the headline):
• Autoimmune mechanism (CD8+/interferon-gamma): Strong (settled).
• Ruxolitinib approved, boxed warning, nonsegmental: Strong (regulatory fact).
• Ruxolitinib repigments faces (~30% F-VASI75 at 24 wk): Moderate (large RCTs, modest, face-only, sponsor-conflicted).
• NB-UVB + topical > monotherapy: Moderate (consistent direction, modest, heterogeneous).
• Thyroid comorbidity (~34% antibody-positive): Strong observational.
• Diet/supplement/detox "cure": Emerging-to-absent (adjunct-only, unproven).
• Lower skin-cancer risk / sun protection for burns+Koebner: Moderate (consistent but observational).

Practical takeaway

The framing to hold: vitiligo is an autoimmune condition with real, approved treatments, and it is not a hygiene, fungal, or diet failing. The treatments repigment slowly and partially, the face responds far better than the hands and feet, and there is no cure — so the plan is a realistic course of evidence-based therapy plus a thyroid check plus protection of the depigmented skin, not a supplement or "detox" purchase.

Drop the wrong models first.
• It is not an infection or a hygiene problem. Antifungal creams and scrubbing do nothing and trauma can make it worse. Stop treating the surface.
• It is not a diet or "toxin" failing. No gluten-free, elimination, or detox regimen is established to repigment skin. Do not spend money or hope there.

The treatments that actually work (managed with a clinician).
• Topical corticosteroids or calcineurin inhibitors: first-line for limited disease, especially on the face; calcineurin inhibitors (tacrolimus, pimecrolimus) are often preferred for the face and around the eyes to avoid steroid thinning — they carry a class boxed warning about a theoretical malignancy risk that dermatology consensus regards as unsupported by the evidence, worth stating honestly rather than dismissing.
• Narrowband UVB phototherapy: the mainstay for more widespread disease, and more effective when combined with a topical than either alone. It is slow and requires repeated sessions.
• Ruxolitinib cream (Opzelura): the first approved repigmentation drug, for nonsegmental vitiligo in patients aged 12+, applied twice daily to no more than 10% of body-surface area. Expect a facial response in a minority by six months and a fuller response over a year; it is not a cure, and it carries a boxed warning worth discussing with the prescriber.

Set expectations honestly before starting.
• The face and neck respond; the hands and feet barely do. Do not promise even repigmentation across the body.
• It is slow and often incomplete. Response is measured over months, and "some repigmentation" is a more realistic goal than "clearance."
• Segmental vitiligo behaves differently. It tends to be localised, stabilise early, and is a different treatment conversation than the nonsegmental form the drug trials address; do not generalise nonsegmental results to it.

Do the cheap, high-value adjacent steps.
• Check the thyroid. Autoimmune thyroid disease is the most common comorbidity; a TSH-plus-antibodies test is low-cost and worthwhile (see thyroid_dysfunction).
• Protect the depigmented skin from burns and trauma. It burns easily and sunburn can seed new patches (Koebner); protect it to avoid burns and new lesions — not because of a cancer scare, since cohorts show lower overall skin-cancer risk. Sunscreen choice and sensible-sun specifics are in sunscreen_mineral_vs_chemical_and_sensible_sun.
• Camouflage is legitimate. Cosmetic camouflage and self-tanners (dihydroxyacetone) are reasonable, low-risk ways to reduce contrast while treatment runs, and matter for the real psychological burden of a visible condition.
• General skincare stays simple. Routine skin care defers to evidence_based_minimal_skincare; there is no special "vitiligo diet" to layer on top.

Evidence detail

Why This Entry Exists

Vitiligo is one of the most misattributed conditions in everyday health talk. Because it presents as visible white patches, it gets read as a fungal skin infection, a sign of poor hygiene, a liver "toxin" problem, or the visible failure of someone's diet — and each of those framings is wrong. Vitiligo is autoimmune: the immune system's CD8+ cytotoxic T cells destroy the melanocytes that make pigment, driven by type-1 cytokines. That single fact reorganises everything downstream. It is why antifungal creams, harsher washing, and "detox" regimens do nothing, and it is why the drugs that genuinely work all target the immune signalling rather than the skin surface.

The entry has to do two opposite jobs at once, and getting the ordering right is the whole point. On one side it must defend that real, approved treatments exist against a fatalistic "nothing can be done, just cover it up" dismissal — because narrowband UVB, topical steroids and calcineurin inhibitors, and now ruxolitinib cream can and do repigment skin, especially on the face. On the other side it must refuse to over-sell those treatments: they are slow, partial, site-dependent, and none of them is a cure, and the pivotal drug trial's headline number is a face-only endpoint that most patients do not even reach. Between those two honest poles sits a large, profitable market of supplements, gluten-free protocols and "natural cures" that exploits exactly the gap the real treatments leave open.

What bad advice this protects against, in all directions:
• "Vitiligo is a fungus / caused by poor hygiene — treat it with antifungals or scrub harder" → it is an autoimmune destruction of melanocytes, not an infection or a cleanliness problem; antifungals and washing do nothing and trauma can make it worse.
• "It's your diet / your liver full of toxins — fix it with a gluten-free or detox protocol" → no diet, gluten-free regimen, or "detox" is established to cause repigmentation; the supplement literature is adjunct-only and explicitly unproven.
• "Nothing can be done, there's no treatment" → the opposite over-correction; topical steroids/calcineurin inhibitors, narrowband UVB, and ruxolitinib cream are real repigmentation therapies with trial evidence.
• "The new JAK cream is basically a cure" → its pivotal endpoint is facial repigmentation of at least 75%, reached by only about 30% of patients at six months and about half at a year; hands and feet barely respond, and it is not a cure.
• "The boxed warning is only about the pills, ignore it on the cream" → the class boxed warning (serious infection, malignancy, cardiovascular events, clots) is on the ruxolitinib cream label; systemic absorption is low but the warning stands and is worth stating honestly.
• "Vitiligo means you're at high risk of skin cancer" → cohorts actually show lower overall skin-cancer risk; sun protection is warranted to prevent burns and new patches, not because of an elevated cancer scare (see sunscreen_mineral_vs_chemical_and_sensible_sun).
• "It's just cosmetic, so it doesn't matter medically" → it carries a real associated-autoimmunity signal, most commonly thyroid disease, which is worth a low-cost check (see thyroid_dysfunction).

This entry owns the autoimmune-versus-hygiene/diet reframe, the evidence-based treatment ladder, realistic repigmentation expectations, the thyroid-comorbidity note, and the supplement/detox debunk. It defers general skincare routine to evidence_based_minimal_skincare and sunscreen choice and sensible-sun mechanics to sunscreen_mineral_vs_chemical_and_sensible_sun, stating those boundaries and routing there rather than re-arguing them.

Evidence

Organised by claim, with the tier signal inline. The pathophysiology and the regulatory facts are the firmest parts; the treatment effect sizes are Moderate and must carry their site-dependence and "no cure" caveats; the supplement/detox claims are effectively unsupported. Read the tiers, not just the thesis.

The condition is autoimmune, not infectious or dietary (Strong mechanistic consensus).

1. Vitiligo is driven by CD8+ cytotoxic T cells destroying melanocytes via type-1 cytokines — it is not fungal, hygienic, or dietary in origin. Infiltrating CD8+ T cells kill melanocytes under an interferon-gamma / TNF-alpha (type-1 cytokine) programme, with impaired regulatory T-cell suppression allowing the attack to proceed; the condition affects ~0.5–1% (up to ~2% in some populations) of the population worldwide. This is the settled pathophysiology, and it is load-bearing for the whole entry: the entire JAK-inhibitor drug class works precisely because it blocks the interferon-gamma / JAK-STAT signalling axis. (Mechanistic reviews and studies of CD8+ cytotoxic-T-cell-mediated melanocyte destruction and impaired Tregs in generalized vitiligo, e.g. PMC3359382; prevalence ~0.5–1% (up to ~2% in some populations) worldwide. Strong Evidence — this is settled mechanism, not a contested claim. Academic mechanistic literature with no single sponsor; the interferon-gamma story is commercially convenient for JAK-inhibitor makers but predates and is independent of them.)

Ruxolitinib cream is the genuine recent advance and the first approved repigmentation drug (Strong for the drug, modest effect).

2. Ruxolitinib cream (a JAK1/2 inhibitor) repigments faces in two large placebo-controlled trials — but most patients do not reach the endpoint. In the two phase-3 TRuE-V trials (n=674 combined), the primary endpoint was F-VASI75, meaning at least 75% facial repigmentation, at 24 weeks: it was reached by 29.8% on ruxolitinib versus 7.4% on vehicle in TRuE-V1, and 30.9% versus 11.4% in TRuE-V2, both statistically significant (P<0.001). About half of patients who continued treatment reached F-VASI75 by 52 weeks. This is the best treatment evidence vitiligo has, and it is also the clearest illustration of the "partial" caveat: roughly two-thirds of treated patients did not hit 75% facial clearance even at six months. (Rosmarin D, et al. "Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo." N Engl J Med 2022, NEJMoa2118828; Incyte 52-week TRuE-V data. Trial-quality is high — two large vehicle-controlled RCTs with a pre-specified significant primary endpoint — but the absolute response is modest, so this reads as Moderate for the real-world claim "it repigments skin." COI: the TRuE-V trials are sponsored by Incyte, which markets the cream as Opzelura; the face-only endpoint flatters the most responsive body site, so report facial, not whole-body, gains.)

3. The FDA approved ruxolitinib cream 1.5% (Opzelura) for nonsegmental vitiligo in patients aged 12+ in July 2022 — carrying a class boxed warning. It is the only approved repigmentation treatment and the only topical JAK inhibitor; it is applied twice daily to no more than 10% of body-surface area, and a full response may take longer than 24 weeks. It carries the JAK-class boxed warning (serious infection, malignancy, major adverse cardiovascular events, thrombosis, mortality), which is derived from oral JAK-inhibitor safety data. (FDA news release, "FDA Approves Topical Treatment Addressing Repigmentation in Vitiligo in Patients Aged 12 and Older," July 2022; OPZELURA prescribing information. Regulatory fact — Strong. Honest caveat: the boxed warning comes from oral-JAK evidence and topical systemic absorption is low, but the warning is on the label and should be stated, not dismissed as "oral only." Incyte product — marketing incentive to downplay the warning.)

Standard first-line therapies work, but slowly, partially, and site-dependently (Moderate).

4. Narrowband UVB phototherapy combined with topical corticosteroids or calcineurin inhibitors outperforms monotherapy — but the gains are modest and strongly site-dependent. Combined narrowband UVB plus a topical (steroid or calcineurin inhibitor) is more effective than either alone, yet the incremental benefit is modest and durability is limited. Response tracks body site sharply: the face and neck respond best (a large fraction of patients get at least mild repigmentation there), while the distal extremities — hands and feet — respond poorly. (Network meta-analysis of combined phototherapy plus topical therapy, J Dermatolog Treat 2025, doi:10.1080/09546634.2025.2483808; systematic review/meta-analysis of topical calcineurin inhibitors, PMC6547091; narrowband UVB reviews. Moderate — consistent direction across meta-analyses, but modest effect sizes, heterogeneous trials, and varying "repigmentation" thresholds. Largely academic/generic-therapy literature with no single sponsor pushing cheap topicals or narrowband UVB, which strengthens credibility relative to the branded-drug data.)

The associated-autoimmunity signal is real and cheap to check (Strong observational).

5. Autoimmune thyroid disease is the most common vitiligo comorbidity, justifying a thyroid check. Roughly a third of vitiligo patients carry positive thyroid antibodies (about 34% in meta-analysis), autoimmune thyroid disease is the most frequent associated condition, and the two share genetic loci (e.g. CTLA4, PTPN22), with supporting Mendelian-randomization evidence. This makes a TSH-plus-antibodies check a reasonable, low-cost step. (Systematic review/meta-analysis of thyroid-disorder prevalence in vitiligo, Front Endocrinol 2018; vitiligo–Hashimoto shared-biomarker and Mendelian-randomization studies, PMC10847670, PMC11133963. Strong observational association plus supporting genetic/MR evidence — actionable and appropriate to state as a check, not a certainty. No commercial driver; if anything under-promoted because no product attaches to "get your thyroid tested." See thyroid_dysfunction.)

No cure, and the diet/supplement/"detox" market is unsupported (weak-to-absent evidence).

6. Vitiligo has no cure, and dietary, supplement, and "detox" cures are not established. The adjunct supplements that appear in the literature — Ginkgo biloba, Polypodium leucotomos, various antioxidants — have only small early RCTs as add-ons to phototherapy, described by the reviews themselves as exploratory rather than curative, and no gluten-free or "detox" regimen is established to repigment skin. The reviews concede that whether diet, vitamins, or supplements benefit vitiligo remains unclear. (Review of dietary/supplement/plant compounds for adjunct vitiligo management, Nutrients 2025, PMC11767946; clinical summaries noting the supplement/diet evidence remains unclear. Emerging-at-best for supplements as adjuncts, and effectively zero for diet/detox "cures" — the reviews' own hedging is the receipt for the debunk. Cui bono the other way: the supplement/"natural cure" market profits directly from selling hope for a chronic, visible, incurable condition, and even the pro-supplement reviews say "more research needed before recommended.")

Sun protection matters — for burns and new patches, not a cancer scare (Moderate, corrects an over-claim).

7. Depigmented skin needs sun protection to prevent burns and new lesions, not because vitiligo raises skin-cancer risk — it appears to lower it. Depigmented patches lack the melanin that buffers UV, so they burn far more easily, and sunburn or trauma can trigger new patches through the Koebner (isomorphic) response, often within one to two weeks. Yet population cohorts paradoxically report lower overall skin-cancer risk (non-melanoma and melanoma) in vitiligo, so the case for sun protection rests on burn prevention and Koebner avoidance, not an elevated cancer threat. (International cross-sectional survey of skin-cancer-risk perception and photoprotection in vitiligo, Arch Dermatol Res 2024, PMC11111492; cohort reviews reporting reduced skin-cancer risk. Moderate — the reduced-cancer finding is consistent across cohorts but observational; the Koebner-from-trauma link is well-described clinically. Honest framing: protect to avoid burns and new patches, not because cancer risk is high. Sun/sunscreen specifics defer to sunscreen_mineral_vs_chemical_and_sensible_sun.)

Mechanism

This entry owns the why it is autoimmune, why the approved drugs work, and why results are partial story, not the full skin-barrier or photobiology detail, which defer to evidence_based_minimal_skincare and sunscreen_mineral_vs_chemical_and_sensible_sun. What follows is only enough mechanism to make the reframe and the treatment ceiling intelligible.

Why it is autoimmune, and why the "infection/hygiene/diet" framings are category errors. In vitiligo, CD8+ cytotoxic T cells home to the skin and kill melanocytes, the cells that produce pigment. Their attack is orchestrated by type-1 cytokines — chiefly interferon-gamma, which drives a chemokine signal (the CXCL9/10–CXCR3 axis) that recruits more cytotoxic T cells — while the regulatory T cells that should dampen the response are functionally impaired. That is a self-directed immune process, not a microbe on the skin and not a nutrient the person is missing. So an antifungal cream has no target, harder washing does nothing, and a "detox" of the liver is treating an organ that has no role here. The patches are white because the pigment factory has been destroyed, not because something dirty has been deposited.

Why the approved drugs work: they interrupt the immune signal, not the skin surface. Interferon-gamma signals through the JAK-STAT pathway inside cells. Ruxolitinib inhibits JAK1 and JAK2, so it blunts that interferon-gamma signal locally, taking the foot off the autoimmune attack and letting surviving and migrating melanocyte precursors — largely from the hair-follicle reservoir — repopulate the skin. Topical corticosteroids and calcineurin inhibitors likewise work by immunosuppression, and narrowband UVB both suppresses the local immune attack and stimulates melanocyte precursors. The common thread is that every effective therapy targets the immune process or the melanocyte reservoir; none of them targets a "surface" problem, which is exactly why surface-level folk remedies fail.

Why results are slow, partial, and site-dependent. Repigmentation depends on a supply of melanocyte precursors to refill the skin, and that supply comes mostly from hair follicles. Facial skin is densely follicular, so it repigments relatively well; the hands and feet (acral skin) have sparse follicles and repigment poorly, which is why the same drug that clears a face barely touches the fingers. And because it is a repopulation process, it is intrinsically slow — measured over months, not weeks — and often incomplete. This is the mechanistic reason the honest verdict is "real treatments, partial results, no cure," and why a face-only trial endpoint over-states whole-body benefit.

Why trauma and sunburn can spread it (the Koebner response). Skin injury — including sunburn, friction, and cuts — can trigger the isomorphic (Koebner) response, seeding new depigmented patches at the site of trauma, often within ten to fourteen days. This is the mechanistic basis for protecting depigmented skin from burns and avoiding unnecessary trauma, and it is a distinct rationale from any cancer concern.

Risks And Contraindications

• Do not treat vitiligo as an infection or a hygiene/diet failing. The dangerous version of this is delay and false blame: reaching for antifungals, harsher washing, or elimination diets while an actual repigmentation window (better the earlier and more active the disease is treated) passes. It is autoimmune; direct effort at the treatments that target the immune process.
• The ruxolitinib boxed warning is real — state it, do not dismiss it. The cream carries the JAK-class boxed warning (serious infection, malignancy, major adverse cardiovascular events, thrombosis, mortality). That warning is derived from oral JAK-inhibitor data, and topical systemic absorption is low, but it is on the label and has not been studied to the same safety depth topically. The honest line is "systemic exposure is low but the warning applies," not "that's only for the pills." Use limited to no more than 10% of body-surface area per the label.
• Do not over-sell repigmentation, especially whole-body. The pivotal endpoint is facial (F-VASI75); only about 30% reach it at 24 weeks and about 50% at a year, and the hands and feet respond poorly. Presenting facial numbers as whole-body clearance, or any therapy as a cure, is the optimistic over-claim to avoid. There is no cure.
• Distinguish segmental from nonsegmental vitiligo. Ruxolitinib is approved for nonsegmental disease; segmental vitiligo is typically localised, stabilises early, and follows a different course, so trial results for one do not transfer to the other.
• Do not endorse supplements or "detox" as treatments. Ginkgo, Polypodium leucotomos, and antioxidants are unproven adjuncts at best (small, phototherapy-add-on trials the reviews call exploratory), and no gluten-free or detox protocol is established. Selling these as cures for a chronic, visible, incurable condition is the classic exploitation to refuse.
• Do not imply vitiligo raises skin-cancer risk. Cohorts show the opposite (lower non-melanoma and melanoma risk). Justify sun protection by burn prevention and Koebner (new-patch) avoidance, and defer sunscreen mechanics to sunscreen_mineral_vs_chemical_and_sensible_sun — do not invent a cancer scare to sell sun protection.
• Take the psychological burden seriously. Vitiligo is visible and can be genuinely distressing; dismissing it as "just cosmetic" is its own harm. Camouflage, realistic treatment framing, and support belong in the plan.

Controversy

Nature: a real autoimmune condition that is widely misattributed to hygiene, infection, or diet, wrapped by a market that sells false cures — with error possible at both poles: fatalistic under-treatment ("nothing works") on one side, and optimistic over-claiming (the new drug is a cure; a supplement or diet will fix it) on the other.

Position A — "Vitiligo has real, evidenced treatments and a real autoimmune basis." The defended-treatment take.
• Best evidence: settled autoimmune mechanism (CD8+ T cells, interferon-gamma/JAK-STAT); two large placebo-controlled phase-3 trials of ruxolitinib cream with a significant facial-repigmentation endpoint; narrowband UVB plus topicals outperforming monotherapy; and a real thyroid-comorbidity signal worth checking. The fungal/hygiene/diet framing is simply wrong.
• Where it goes wrong if overstated: it slides into "the JAK cream is a cure," generalises facial repigmentation to the whole body, or ignores the boxed warning.

Position B — "The results are partial and the cure market is unsupported." The honest-counter take.
• Best evidence: no cure exists; repigmentation is slow, partial, and site-dependent (face responds, hands/feet barely); even the best drug's facial endpoint is reached by only ~30% at six months; and the diet/supplement/detox "cure" market is unsupported by the very reviews that examine it.
• Where it goes wrong if overstated: it can tip into "nothing can be done," which ignores the genuine repigmentation therapies and abandons treatable patients.

The funding/bias dimension — cui bono, both ways. Two profit vectors pull in opposite directions. Toward over-claiming the drug: the pivotal ruxolitinib evidence (TRuE-V1/V2) is Incyte-sponsored, Incyte markets Opzelura as the first-and-only approved repigmentation drug, and the face-only primary endpoint flatters the most responsive site; independent replication and durable whole-body data are the check. Toward over-claiming natural cures: the supplement, gluten-free, and "detox" market profits directly from selling hope for a chronic, visible, incurable, psychologically distressing condition, and does so on evidence its own sympathetic reviews call unestablished. The conflict-clean anchors — the autoimmune mechanism, the regulatory facts, and the reduced-skin-cancer cohort finding — come from academic sources with no product to sell.

Realised Position: Both hold, and they are not in tension once ordered correctly. Vitiligo is a genuine autoimmune condition with genuine, approved treatments, so the fungal/hygiene/diet framing is wrong and worth debunking plainly — and those treatments are slow, partial, and site-dependent with no cure, so the counsel is realistic expectations, a thyroid check, and burn/Koebner protection of depigmented skin, not the supplement-and-detox cure market. Report facial (not whole-body) repigmentation numbers, state the boxed warning honestly rather than waving it away, and treat the diet/supplement "cures" as unsupported.

Cross-Pillar Connections

Vitiligo is an autoimmune skin condition with systemic and lifestyle tails, so its connections span the immune, endocrine, skincare, and evidence-literacy lines.
• Conditions / immune (immune_function_cross_pillar_optimisation): vitiligo is an autoimmune process, so it sits inside the broader immune-regulation picture; this entry holds the vitiligo-specific mechanism and defers general immune framing there.
• Metabolic/Hormonal (thyroid_dysfunction): autoimmune thyroid disease is the most common vitiligo comorbidity; this entry holds only that a thyroid check is warranted and defers thyroid workup and management there.
• Skin (evidence_based_minimal_skincare): owns the general skincare routine; this entry holds only the vitiligo-specific treatment ladder and defers baseline skin care there rather than re-arguing it.
• Skin/sun (sunscreen_mineral_vs_chemical_and_sensible_sun): owns sunscreen choice and sensible-sun mechanics; this entry holds only that depigmented skin needs protection from burns and Koebner-triggering trauma (not because of elevated cancer risk) and defers the how-to there.
• Foundations (publication_bias_and_evidence_distortion): the mechanism behind both the sponsor-flattered drug endpoint and the false-cure supplement claims that inflate or fabricate vitiligo's apparent options.

What would change our mind

Falsifiability: explicit upgrade/downgrade criteria from source

• We'd upgrade the treatment claims toward Strong if independent (non-Incyte) phase-3 or head-to-head RCTs showed durable whole-body (not just facial) repigmentation that held up after stopping treatment. The current anchor is a manufacturer-sponsored pair of trials with a face-only endpoint.
• We'd move the supplement/diet debunk if a well-powered RCT of a specific diet or supplement showed repigmentation as monotherapy (not merely as an add-on to phototherapy) against a hard endpoint. Right now the literature is adjunct-only and self-described as exploratory.
• We'd sharpen the safety framing if long-term pharmacovigilance on topical ruxolitinib quantified systemic JAK-related events, letting the boxed-warning discussion rest on topical-specific data rather than extrapolation from oral drugs.
• We'd revise the sun-protection rationale if a rigorous cohort reversed the lower-skin-cancer-risk finding; the case would then rest partly on cancer risk rather than only on burns and Koebner.
• What would NOT move us: the autoimmune mechanism, the fact that antifungals/hygiene/detox do nothing, or that there is currently no cure — these are settled and the bias vector on the "natural cure" side runs toward over-claiming.

Industry bias note

Structural incentives the evidence base may reflect

Cui bono runs in two opposite directions here, and naming both is the point.
• Pharma pulls toward over-claiming the drug. The pivotal ruxolitinib evidence (TRuE-V1 and TRuE-V2) is Incyte-sponsored, and Incyte markets Opzelura as the first and only approved repigmentation drug. The face-only primary endpoint (F-VASI75) flatters the most responsive body site, and the "first-in-class" framing invites treating a modest, partial result as a breakthrough cure. The check is to report facial (not whole-body) gains, note that most treated patients did not reach the endpoint at six months, and state the boxed warning honestly. Independent, non-manufacturer whole-body and durability data are what would settle it.
• The wellness/supplement/"detox" market pulls toward false cures. It profits directly from selling hope for a chronic, visible, incurable, psychologically distressing condition — Ginkgo, Polypodium, antioxidants, gluten-free protocols, and "detox" regimens marketed as cures when even sympathetic reviews call them unestablished adjuncts. This is the more predatory bias vector because it targets desperation and charges for it.
• The conflict-clean anchors go the other way. The autoimmune mechanism, the regulatory facts, and the lower-skin-cancer-risk cohort finding come from academic sources with no product to sell — which is exactly why they are trustworthy, and why the entry leans on them to bound both over-claims. Notably, "get your thyroid tested" is under-promoted precisely because no product attaches to it.
• Net pattern: trust the mechanism and the regulatory facts, report the modest and site-dependent effect sizes honestly, weight the sponsor-conflicted drug trial as real-but-flattered, and treat the diet/supplement/detox cure claims as unsupported (see publication_bias_and_evidence_distortion).

Vitiligo: An Autoimmune Condition With Real Treatments, Not a Diet Failing